Merck & Co., Inc. reported positive Phase 2 results from the CADENCE trial evaluating WINREVAIR (sotatercept-csrk) in adults with combined post- and precapillary pulmonary hypertension associated with Heart Failure with Preserved Ejection Fraction. The study demonstrated proof-of-concept that targeting activin signaling can improve pulmonary vascular hemodynamics in this complex patient population, a group historically underserved by existing therapies.

The significance of these results lies less in incremental efficacy and more in what they validate mechanistically. Combined post- and precapillary pulmonary hypertension, often referred to as CpcPH, sits at the intersection of left heart disease and pulmonary vascular remodeling. Traditional therapies have struggled because they tend to address either left-sided filling pressures or pulmonary arterial resistance, but not both in a coordinated manner. Industry observers note that sotatercept’s mechanism, which modulates bone morphogenetic protein signaling and vascular remodeling pathways, introduces a fundamentally different approach that targets disease biology rather than symptomatic hemodynamics alone.

Why targeting vascular remodeling in CpcPH may address a long-standing therapeutic gap in HFpEF populations

The CADENCE data reinforces a growing view among clinicians that vascular remodeling is not merely a downstream consequence of HFpEF but an active driver of disease progression in certain subgroups. Patients with CpcPH exhibit elevated pulmonary vascular resistance layered on top of elevated left-sided pressures, creating a dual burden that worsens outcomes and limits treatment options.

Historically, pulmonary arterial hypertension drugs such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors have shown inconsistent or negative results in HFpEF populations. Regulatory watchers suggest this reflects a mismatch between drug mechanism and disease biology. In contrast, sotatercept’s ability to rebalance pro-proliferative and anti-proliferative signaling pathways may directly address the vascular component that distinguishes CpcPH from isolated postcapillary pulmonary hypertension.

The implication is that sotatercept could define a new subclass of therapies aimed at mixed-etiology pulmonary hypertension, where the disease cannot be cleanly categorized under existing treatment paradigms. This is particularly relevant as HFpEF prevalence continues to rise globally, bringing with it an increasing burden of secondary pulmonary vascular complications.

What the CADENCE trial design and endpoints reveal about clinical credibility and translational potential

From a clinical development perspective, the CADENCE trial appears designed to answer a specific and historically elusive question: can modifying vascular remodeling translate into measurable hemodynamic and functional improvements in a heterogeneous HFpEF population.

While full details of endpoints and statistical robustness will determine how regulators interpret the data, early indications suggest meaningful improvements in pulmonary vascular resistance and related hemodynamic parameters. Clinicians tracking the field believe that these endpoints, while surrogate in nature, are highly relevant in a condition where mortality trials are difficult due to heterogeneity and comorbidities.

However, limitations remain. HFpEF itself is a syndrome rather than a single disease entity, with multiple phenotypes driven by obesity, metabolic dysfunction, aging, and inflammation. The extent to which CADENCE participants represent a clearly defined CpcPH subgroup will be critical in determining reproducibility. Industry observers caution that signal dilution in broader populations has historically undermined promising therapies in HFpEF.

How sotatercept’s expansion beyond pulmonary arterial hypertension could reshape its commercial and clinical trajectory

Sotatercept has already established clinical relevance in pulmonary arterial hypertension, where disease biology, regulatory pathways, and treatment algorithms are relatively well defined. Expanding into combined post- and precapillary pulmonary hypertension linked to heart failure with preserved ejection fraction introduces a materially larger but more complex opportunity set, as the addressable population expands alongside rising HFpEF prevalence. This shift moves the therapy into a setting where disease heterogeneity, comorbid burden, and diagnostic variability are significantly higher, raising the bar for both clinical differentiation and real-world implementation.

Industry observers suggest that success in this setting will depend less on broad adoption and more on the ability to define and target responder populations with precision. This may require tighter phenotyping using invasive hemodynamics, imaging, or emerging biomarker strategies to distinguish patients with true vascular remodeling from those driven primarily by left-sided pressure overload. Without this level of segmentation, there is a risk that efficacy signals become diluted in broader populations, which has historically limited adoption and reimbursement for therapies entering the HFpEF space despite promising early data.

What regulatory pathways and evidence thresholds could determine approval prospects in this indication

Regulatory clarity remains an open question. While proof-of-concept data is encouraging, advancing from Phase 2 to approval in a heterogeneous condition like CpcPH will likely require carefully designed Phase 3 trials with robust endpoints.

Regulators may accept hemodynamic improvements as supportive evidence, but long-term outcomes such as hospitalization rates, functional capacity, and quality of life will likely play a central role. The challenge lies in balancing trial feasibility with evidentiary rigor in a population where comorbidities complicate endpoint interpretation.

There is also the question of indication labeling. Whether sotatercept would be approved broadly for CpcPH or restricted to specific HFpEF subgroups will influence both clinical adoption and market penetration. Industry observers note that a narrower label may accelerate approval but limit commercial upside, while a broader label increases regulatory risk.

What adoption, reimbursement, and real-world implementation challenges could limit scalability

Even if regulatory hurdles are cleared, real-world adoption will depend on several structural factors. Diagnosing CpcPH requires invasive hemodynamic assessment, typically via right heart catheterization, which is not uniformly performed across all HFpEF patients. This creates a bottleneck in identifying eligible patients.

Reimbursement dynamics will also play a critical role. High-cost therapies in cardiovascular disease are increasingly scrutinized, particularly when benefits are incremental or confined to subpopulations. Payers may require evidence of cost-effectiveness or restrict use to specialized centers.

Clinicians tracking the field also highlight operational challenges. Integrating a therapy like sotatercept into HFpEF management pathways will require coordination between cardiologists and pulmonary hypertension specialists, a level of multidisciplinary care that is not consistently available.

What unresolved questions and risks remain as sotatercept moves toward later-stage development

Despite the positive signal, several uncertainties remain. Long-term safety will be closely monitored, particularly given the systemic effects of modulating growth factor signaling pathways. Off-target effects or unforeseen complications could emerge with broader use.

There is also the question of durability. Whether the hemodynamic improvements observed in CADENCE translate into sustained clinical benefit over years rather than months remains to be seen. Clinicians emphasize that short-term improvements in surrogate endpoints do not always correlate with long-term outcomes in complex cardiovascular diseases.

Finally, competitive dynamics cannot be ignored. Other companies are exploring alternative pathways in pulmonary hypertension and HFpEF, including anti-inflammatory approaches, metabolic modulators, and novel vasodilators. The extent to which sotatercept can maintain differentiation will depend on continued clinical validation and real-world performance.

What evidence, patient selection strategy, and long-term outcomes will define sotatercept-csrk’s next phase of validation

The next phase of development will likely focus on confirming efficacy in larger, more precisely defined populations while addressing safety and durability concerns. Regulators will scrutinize trial design and endpoint selection, while clinicians will look for clarity on patient selection and real-world applicability.

Industry observers suggest that the broader implication of the CADENCE data extends beyond a single drug. If sotatercept continues to demonstrate benefit, it could validate vascular remodeling as a central therapeutic target in HFpEF-related pulmonary hypertension, potentially opening the door for a new class of therapies.

Currently, the results represent a meaningful step forward in a field that has seen repeated setbacks. Whether this translates into a durable shift in treatment paradigms will depend on the strength of subsequent evidence and the ability to navigate the complex clinical and regulatory landscape ahead.

  CADENCE trial, cardiovascular therapeutics, clinical trials, HFpEF, Inc., Merck & Co., pulmonary hypertension, sotatercept-csrk, WINREVAIR